Pricing Log in Create free account
Friday 6 November 2026 Export ALNY’s income statement to Excel — free account

Alnylam Pharmaceuticals, Inc.

ALNY Healthcare Biotechnology

Alnylam Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $3.7 billion, up 65.2% from fiscal 2024.

Revenue
+16.7%
EPS
+747.6%
Free cash flow
−4.76%
Total debt
−2.66%

Quarter to September 2026, against a year earlier

156.26 0.40 −0.26%
Market cap
$21.0B
P/E
7.9×
Fwd P/E
13.5×
Dividend yield
—
F-score
6/9
Altman Z
7.30
Beneish M
−1.95
Dividend safety
n/a
Overview Business Profile Earnings & Analysis
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios
Segments Valuation Filings

Alnylam Pharmaceuticals, Inc. 10-Q filed Oct 29, 2026

Fiscal Q3 2026 · Period ended Sep 30, 2026 · Filed · accepted 8:20 AM ET · Document on sec.gov · Filing index

What changed

Part I, Item 2, Management’s Discussion and Analysis Part II, Item 1A, Risk Factors

Part II, Item 1A, Risk Factors, against the 10-Q filed Jul 30, 2026: 4 added · 2 removed · 84 modified; 4 with only figures updated

90 more changes in this Item, word by word, in Powerpack.